Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
General Medicine
Reference37 articles.
1. Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment;Aris;Front Immunol,2015
2. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma;Faghfuri;Expert Rev Anticancer Ther,2015
3. Nivolumab in the treatment of malignant melanoma: review of the literature;Mashima;Onco Targets Ther,2015
4. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma clinical therapeutics;Mahoney;Clin Ther,2015
5. A systemic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/P D-L1, and HLA-G;Carosella;Eur Urol,2015
Cited by 83 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Complete Response to Pembrolizumab in Stage IV Alveolar Soft Part Sarcoma After Failure of Four Lines of Treatment: A Case Report and Literature Review;Cureus;2024-06-10
2. The nutrition‐related adverse events associated with immune checkpoint inhibitor treatment for patients with non‐small cell lung cancer: A systematic review;Nutrition & Dietetics;2024-05-28
3. Impact of neoadjuvant immunotherapy on postoperative complications after surgery for rectal cancer;Journal of Surgical Oncology;2024-05-27
4. Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy;Cancer Cell;2024-05
5. Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma;Melanoma Research;2024-03-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3